|
|
Article: Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify to Garner 12% of the Schizophrenia Market in 2012; Schizophrenia Market to Face Tough Generic Erosion Starting in 2007, According to a New Study from Decision Resources.
- Article from:
- PR Newswire
- Article date:
- June 16, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WALTHAM, Mass. -- WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify will garner 12% of the schizophrenia market in 2012 when it emerges as a first-choice therapy for treatment of the disease. The new Pharmacor study entitled Schizophrenia also reports that the schizophrenia market will face tough generic erosion after 2006.
"The impact of generics will be the greatest in the United States, where the market will experience a 4.7% annual decline during 2007-2012," said Michelle ...
Related newspaper, magazine, and journal articles:
|
|
Article: Decision Resources, Inc. Acquires Arlington Medical ...
PR Newswire;
December 19, 2007 ;
700+ words
...Acquisition Expands Decision Resources, Inc.'s Market Research ... Dec. 19 /PRNewswire/ -- Decision Resources, Inc., one of the world ... AMR by Waltham, MA-based Decision Resources, Inc. will result in a significant ...
|
|